Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Trial Profile

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimatoprost (Primary) ; Timolol
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ARTEMIS; ARTEMIS 2
  • Sponsors AbbVie; Allergan
  • Most Recent Events

    • 01 Jan 2023 Results from NCT02247804 and NCT02250651; evaluating the time course of biodegradation of an intracameral, biodegradable, sustained-release bimatoprost implant that lowers intraocular pressure without the need for daily eye drops, published in the Journal of Ocular Pharmacology and Therapeutics
    • 28 May 2022 Results of a pooled analysis of data from 2 phase III studies and one phase I/II study (NCT02247804, NCT02250651, and NCT01157364) assessed the single administration of intracameral Bimatoprost implant 10 µg in patients with Open-Angle Glaucoma or Ocular Hypertension, published in the Ophthalmology and Therapy
    • 01 Nov 2021 Primary endpoint has been met. (Change From Baseline in Intraocular Pressure (IOP) in the Study Eye to Week 12 (Hours 0 and 2) for 15 g), as per Results published in the Drugs
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top